For customers outside of Japan
Thanks to a favorable tax climate, efficient regulatory policies and world-class research sector for phase I, phase II and phase III activities, EPS has had a solid presence in Australia since 2006. The popularity of Australia as a destination for clinical trials has exploded in the 21st century. Since 2003 there has been a 10-fold increase in the number of trials (2016 figures). The country's cutting-edge clinical trial diagnostics and advanced monitoring facilities make it ideal for clinical research, especially in the field of oncology.
Health Expenditure per Capita
Source: Financing Global Health Database 2018
Source: The World Bank
Burden of Disease DALYs Causes % of Total DALYs
(2017, all ages/both sexes)
Low back Pain (6.11%)
Ischemic heart disease (5.94%)
Chronic obstractive pulmonary
Source: Institute Health Matrics and Evaluation GBD
NDA Approval Time
Phase 1 clinical trial opportunities: Australia shows the world it's open for business
Clinical trial opportunities are booming in Australia as companies around the world look for new ways to secure reliable data and get ahead of their competitors. Australia is growing rapidly as a research centre, with 1,700 new clinical trials ...
For global cancer clinical trials, Australia is a premium location
Cancer Australia, an Australian government agency, estimated new cancer cases diagnosed in 2016 at 130,466. Cancer Australia also estimated the number of deaths from cancer in 2016 at 46,880 ...
Share this page